Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the ...

The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive ...

Roche’s decision to discontinue the Ionis-partnered trials came soon after the biotech sustained a late-stage failure in ATTR-CM. Roche has discontinued two Huntington’s disease studies for ...

An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, ...

The FDA greenlit 26 novel therapies in the first half of 2026, including four for cancer and six for orphan indications. Meanwhile, AstraZeneca and Johnson and Johnson took home a combined 11 of the ...

The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective. AstraZeneca and Ionis ...

GSK and Alector first partnered in 2021 to advance two antibodies for neurodegenerative diseases. Both assets have since failed to show significant clinical benefit. GSK is officially walking away ...

With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts ...

Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up. Buoyed by new findings from ...

Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space. Kalohexis, a recently spunout ...

Vertex Pharamceuticals shocked analysts this week with the biggest M&A deal in the company’s history. The cystic fibrosis drugmaker is buying Crinetics Pharmaceuticals for $10 billion, notching one of ...

In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered ...